DRUG Stock — Bright Minds Biosciences Inc.

Bright Minds Biosciences Inc. (DRUG)

Updated October 16, 2026.

DRUG is a Stock. Total return is 90.0% over the past 5.6 years, 19.2 points behind SPY at 109.2%.

Bright Minds Biosciences is a biotechnology company developing therapeutic candidates targeting neurological and psychiatric disorders, including serotonin receptor agonists for epilepsy and neuropsychiatric conditions, as well as a treatment for Prader-Willi Syndrome. The company is in early-to-mid stage clinical development with multiple candidates in phase 1 and phase 2 trials. This company does not currently distribute dividends and is oriented toward growth-focused investors rather than income generation.

DRUG performance versus SPY

Price and return data through 2026-10-16.

Total return is 90.0% over the past 5.6 years, 19.2 points behind SPY at 109.2%. Over the past year its total return — price change plus distributions reinvested — is -22.7%. Its deepest 1-year drawdown was 49.7%.

DRUG key facts

Asset type

Stock

Asset class

Equity

Inception date

03/22/2021

Distribution frequency

None

Last close

$51.30 (as of 2026-10-16)

Market cap

$506,026,329

Average volume

56027.0

Beta

0.234

Payout ratio

0.0%

EPS

$-2.13

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

DRUG risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 49.7%.

Who may consider DRUG — and who may not

It is a weaker fit for investors who need monthly cash flow (DRUG does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on DRUG

• All tickers starting with D

Tagged: Healthcare.

Frequently asked questions